Latigo targets $272M+ IPO to fund rival Nav1.8 pain drug to Vertex’s Journavx on August 04, 2026 Abdominoplasty (procedure) Acute onset pain Biotherapeutics Goldman Sachs IPO Jefferies Journavx Latigo Leerink Partners LTGO Nav1.8 inhibitor non-opioid pain drug Silver bunionectomy Suzetrigine +
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic on March 17, 2025 Acute onset pain Biotherapeutics Chronic pain Clinical Trials inhibitors Latigo non-opioid pain drugs SCN10A gene Series B +